Yüklüyor......
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
BACKGROUND: Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Adm...
Kaydedildi:
| Yayımlandı: | J Pharm Policy Pract |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859615/ https://ncbi.nlm.nih.gov/pubmed/31832207 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40545-019-0193-y |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|